Your browser doesn't support javascript.
loading
Histo-Blood Group Antigen Null Phenotypes Associated With a Decreased Risk of Clinical Rotavirus Vaccine Failure Among Children <2 Years of Age Participating in the Vaccine Impact on Diarrhea in Africa (VIDA) Study in Kenya, Mali, and the Gambia.
Schwartz, Lauren M; Oshinsky, Jennifer; Reymann, Mardi; Esona, Mathew D; Bowen, Michael D; Jahangir Hossain, M; Zaman, Syed M A; Jones, Joquina Chiquita M; Antonio, Martin; Badji, Henry; Sarwar, Golam; Sow, Samba O; Sanogo, Doh; Keita, Adama Mamby; Tamboura, Boubou; Traoré, Awa; Onwuchekwa, Uma; Omore, Richard; Verani, Jennifer R; Awuor, Alex O; Ochieng, John B; Juma, Jane; Ogwel, Billy; Parashar, Umesh D; Tate, Jacqueline E; Kasumba, Irene N; Tennant, Sharon M; Neuzil, Kathleen M; Rowhani-Rahbar, Ali; Elizabeth Halloran, M; Atmar, Robert L; Pasetti, Marcela F; Kotloff, Karen L.
Afiliação
  • Schwartz LM; Department of Epidemiology, School of Public Health, University of Washington, Seattle, Washington, USA.
  • Oshinsky J; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Reymann M; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
  • Esona MD; Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.
  • Bowen MD; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
  • Jahangir Hossain M; Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.
  • Zaman SMA; Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Jones JCM; Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Antonio M; Medical Research Council Unit, The Gambia at the London School of Hygiene & Tropical Medicine, Banjul, The Gambia.
  • Badji H; Medical Research Council Unit, The Gambia at the London School of Hygiene & Tropical Medicine, Banjul, The Gambia.
  • Sarwar G; Medical Research Council Unit, The Gambia at the London School of Hygiene & Tropical Medicine, Banjul, The Gambia.
  • Sow SO; Medical Research Council Unit, The Gambia at the London School of Hygiene & Tropical Medicine, Banjul, The Gambia.
  • Sanogo D; Medical Research Council Unit, The Gambia at the London School of Hygiene & Tropical Medicine, Banjul, The Gambia.
  • Keita AM; Medical Research Council Unit, The Gambia at the London School of Hygiene & Tropical Medicine, Banjul, The Gambia.
  • Tamboura B; Centre pour le Développement des Vaccins du Mali, Bamako, Mali.
  • Traoré A; Centre pour le Développement des Vaccins du Mali, Bamako, Mali.
  • Onwuchekwa U; Centre pour le Développement des Vaccins du Mali, Bamako, Mali.
  • Omore R; Centre pour le Développement des Vaccins du Mali, Bamako, Mali.
  • Verani JR; Centre pour le Développement des Vaccins du Mali, Bamako, Mali.
  • Awuor AO; Centre pour le Développement des Vaccins du Mali, Bamako, Mali.
  • Ochieng JB; Kenya Medical Research Institute, Center for Global Health Research, Kisumu, Kenya.
  • Juma J; Division of Global Health Protection, US Centers for Disease Control and Prevention, Nairobi, Kenya.
  • Ogwel B; Kenya Medical Research Institute, Center for Global Health Research, Kisumu, Kenya.
  • Parashar UD; Kenya Medical Research Institute, Center for Global Health Research, Kisumu, Kenya.
  • Tate JE; Kenya Medical Research Institute, Center for Global Health Research, Kisumu, Kenya.
  • Kasumba IN; Kenya Medical Research Institute, Center for Global Health Research, Kisumu, Kenya.
  • Tennant SM; Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Neuzil KM; Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Rowhani-Rahbar A; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
  • Elizabeth Halloran M; Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.
  • Atmar RL; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
  • Pasetti MF; Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.
  • Kotloff KL; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Clin Infect Dis ; 76(76 Suppl1): S153-S161, 2023 04 19.
Article em En | MEDLINE | ID: mdl-37074435
ABSTRACT

BACKGROUND:

Previously studied risk factors for rotavirus vaccine failure have not fully explained reduced rotavirus vaccine effectiveness in low-income settings. We assessed the relationship between histo-blood group antigen (HBGA) phenotypes and clinical rotavirus vaccine failure among children <2 years of age participating in the Vaccine Impact on Diarrhea in Africa Study in 3 sub-Saharan African countries.

METHODS:

Saliva was collected and tested for HBGA phenotype in children who received rotavirus vaccine. The association between secretor and Lewis phenotypes and rotavirus vaccine failure was examined overall and by infecting rotavirus genotype using conditional logistic regression in 218 rotavirus-positive cases with moderate-to-severe diarrhea and 297 matched healthy controls.

RESULTS:

Both nonsecretor and Lewis-negative phenotypes (null phenotypes) were associated with decreased rotavirus vaccine failure across all sites (matched odds ratio, 0.30 [95% confidence interval 0.16-0.56] or 0.39 [0.25-0.62], respectively]. A similar decrease in risk against rotavirus vaccine failure among null HBGA phenotypes was observed for cases with P[8] and P[4] infection and their matched controls. While we found no statistically significant association between null HBGA phenotypes and vaccine failure among P[6] infections, the matched odds ratio point estimate for Lewis-negative individuals was >4.

CONCLUSIONS:

Our study demonstrated a significant relationship between null HBGA phenotypes and decreased rotavirus vaccine failure in a population with P[8] as the most common infecting genotype. Further studies are needed in populations with a large burden of P[6] rotavirus diarrhea to understand the role of host genetics in reduced rotavirus vaccine effectiveness.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 / 3_ND Base de dados: MEDLINE Assunto principal: Infecções por Rotavirus / Antígenos de Grupos Sanguíneos / Rotavirus / Vacinas contra Rotavirus Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Humans País/Região como assunto: Africa Idioma: En Revista: Clin Infect Dis Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 / 3_ND Base de dados: MEDLINE Assunto principal: Infecções por Rotavirus / Antígenos de Grupos Sanguíneos / Rotavirus / Vacinas contra Rotavirus Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Humans País/Região como assunto: Africa Idioma: En Revista: Clin Infect Dis Ano de publicação: 2023 Tipo de documento: Article